

UC San Diego

UC San Diego Previously Published Works

Title

Multi-center screening of the Pathogen Box collection for schistosomiasis drug discovery

Permalink

<https://escholarship.org/uc/item/3937v5z0>

Journal

Parasites & Vectors, 12(1)

ISSN

1756-3305

Authors

Maccesi, Martina
Aguiar, Pedro HN
Pasche, Valérian
et al.

Publication Date

2019-12-01

DOI

10.1186/s13071-019-3747-6

Peer reviewed

RESEARCH

Open Access



Multi-center screening of the Pathogen Box collection for schistosomiasis drug discovery

Martina Maccesi^{1†}, Pedro H. N. Aguiar^{2†}, Valérian Pasche^{3,4†}, Melody Padilla¹, Brian M. Suzuki¹, Sandro Montefusco^{1,5}, Ruben Abagyan¹, Jennifer Keiser^{3,4*} , Marina M. Mourão^{2*} and Conor R. Caffrey^{1*}

Abstract

Background: Over the past five years, as a public service to encourage and accelerate drug discovery for diseases of poverty, the Medicines for Malaria Venture (MMV) has released box sets of 400 compounds named the Malaria, Pathogen and Stasis Boxes. Here, we screened the Pathogen Box against the post-infective larvae (schistosomula) of *Schistosoma mansoni* using assays particular to the three contributing institutions, namely, the University of California San Diego (UCSD) in the USA, the Swiss Tropical and Public Health Institute (Swiss TPH) in Switzerland, and the Fundação Oswaldo Cruz (FIOCRUZ) in Brazil. With the same set of compounds, the goal was to determine the degree of inter-assay variability and identify a core set of active compounds common to all three assays. New drugs for schistosomiasis would be welcome given that current treatment and control strategies rely on chemotherapy with just one drug, praziquantel.

Methods: Both the UCSD and Swiss TPH assays utilize daily observational scoring methodologies over 72 h, whereas the FIOCRUZ assay employs XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide) at 72 h to measure viability as a function of NAD⁺/NADH redox state. Raw and transformed data arising from each assay were assembled for comparative analysis.

Results: For the UCSD and Swiss TPH assays, there was strong concordance of at least 87% in identifying active and inactive compounds on one or more of the three days. When all three assays were compared at 72 h, concordance remained a robust 74%. Further, robust Pearson's correlations (0.48–0.68) were measured between the assays. Of those actives at 72 h, the UCSD, Swiss TPH and FIOCRUZ assays identified 86, 103 and 66 compounds, respectively, of which 35 were common. Assay idiosyncrasies included the identification of unique compounds, the differential ability to identify known antischistosomal compounds and the concept that compounds of interest might include those that *increase* metabolic activity above baseline.

Conclusions: The inter-assay data generated were in good agreement, including with previously reported data. A common set of antischistosomal molecules for further exploration has been identified.

Keywords: *Schistosoma*, Schistosomiasis, Drug discovery, Phenotypic screen, Pathogen Box, MMV

*Correspondence: jennifer.keiser@swisstph.ch; marina.mourao@fiocruz.br; ccaffrey@ucsd.edu

[†]Martina Maccesi, Pedro H. N. Aguiar and Valérian Pasche contributed equally to this work

¹ Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA

² Laboratório de Helminologia e Malacologia Médica, René Rachou Institute, FIOCRUZ, Belo Horizonte, Minas Gerais, Brazil

³ Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, P.O. Box, 4002 Basel, Switzerland
Full list of author information is available at the end of the article

Background

Schistosomiasis is a parasitic disease caused by trematodes of the genus *Schistosoma*. The disease is endemic in 78 countries and preventive chemotherapy of at least 206 million people was necessary in 2016 [1]. Of concern for such a prevalent disease, treatment and control relies on mass chemotherapy with just one drug, praziquantel (PZQ) [2, 3]. PZQ is safe, active against all species of *Schistosoma* and is affordable, or distributed free



of charge. However, the increasing distribution of what is very often a sub-curative drug may encourage the emergence of PZQ-tolerant, or worse, PZQ-resistant parasites [3–5], an alarming prospect in the absence of any back-up drug.

Unlike the case for other global infectious diseases of poverty, schistosomiasis has lacked the prioritization necessary to establish trans-national, public-private drug development programmes that support the synthesis of small molecule chemical libraries, high throughput screening systems and the discovery expertise to identify and advance compounds to the clinic. Allied to this is the greater difficulty, logistics and costs needed to maintain and handle the schistosome parasite compared to the self-replicative single-celled organisms like malaria or the kinetoplastid parasites that are relatively easy to culture and amenable to automated liquid handling robotics. Accordingly, schistosome drug discovery remains fragmented across the academic sector with its more limited resources.

In the last decade, the realization that the ever-increasing distribution of just one drug to sustain the management of schistosomiasis is untenable has motivated the development of a number of phenotypic screening paradigms to identify new small molecules of interest. Many of these have coalesced around the application of *Schistosoma mansoni* schistosomula (post-infective larvae) [6–8]. These can be harvested in their tens of thousands, are reasonably amenable to liquid handling and have been used as the entry-point to screening and triaging the larger ‘industrial-scale’ of small molecule collections for subsequent tests against the more limiting adult parasite which, although directly responsible for disease morbidity *via* their eggs, can only be obtained in small numbers and from small vertebrate animals. A plethora of schistosomula assays with different read-outs has been developed [6, 8–11].

Over the same period, the Medicines for Malaria Venture (MMV) has made available to the drug discovery community a number of box sets each containing 400 well-annotated small molecules that have been validated in various disease contexts. These include the Malaria Box [12], Pathogen Box [13], Stasis Box and, most recently, the Pandemic Box. All, bar the last box, have been screened against schistosomes in culture/*in vivo* and the data made publicly available [12, 14–16]. Because the general interpretability of data arising from the phenotypic screening of schistosomula with the various MMV-supplied boxes (and other small molecules) may have been influenced by the particular assay methodology employed, we took the opportunity to perform an inter-institutional phenotypic evaluation of the Pathogen Box. The study involved teams from the University

of California San Diego (UCSD), the Swiss Tropical and Public Health Institute (Swiss TPH), and the Fundação Oswaldo Cruz (FIOCRUZ). With the same chemical matter in hand, the goals were to identify a core set of active anti-schistosomal compounds of interest for future preclinical pursuit and highlight some distinct features of each particular assay.

Methods

Compounds

The Pathogen Box collection contains 400 compounds distributed in five 96-well plates and dissolved in 10 μ l of pure dimethyl sulfoxide (DMSO) at a concentration of 10 mM. Plates were shipped on dry ice to each of the three institutions by the MMV. Supporting information for the compound collection can be found at <https://www.mmv.org/mmv-open>.

Life-cycle of *S. mansoni* at UCSD and preparation of schistosomula

The NMRI isolate of *S. mansoni* is maintained by passage through *Biomphalaria glabrata* snails (NMRI line) and 3–5 week-old, female Golden Syrian hamsters (Envigo, Placentia, CA, USA) as intermediate and definite hosts, respectively [6, 17]. The acquisition, preparation and *in vitro* maintenance of post-infective larvae (schistosomula) are described as follows. Briefly, infected patent snails were induced to shed infective larvae (cercariae) under a lamp for up to 2 h. Cercariae were concentrated over ice for up to 1 h and then mechanically transformed to schistosomula *via* tail-shearing through a 22 gauge micro-emulsifying needle attached to two 10 ml syringes (passed back and forth 12 times) [18]. Schistosomula were washed in ice-chilled Basch Medium 169 [19] (containing 100 U/ml penicillin and 100 mg/ml streptomycin). Schistosomula were collected and washed three times in the same medium and kept on ice for a maximum of 1 h before distribution into assay plates containing compounds.

In vitro phenotypic assay of schistosomula at UCSD

The assay was performed as described [6, 20, 21]. Essentially, stock Pathogen Box compounds were diluted in DMSO to a 2 mM concentration and 1 μ l manually spotted into transparent, U-bottomed 96-well assay plates (Costar 3367). Chilled Basch Medium 169 (100 μ l; containing 100 U/ml penicillin, 100 mg/ml streptomycin and 4% heat-inactivated FBS (Corning Mediatech, New York, USA) was then added to mix the compound and this was followed by another 100 μ l of medium containing 40–50 schistosomula. The final concentration of compound and DMSO was 10 μ M and 0.5%, respectively. Each compound was tested in duplicate and solvent controls,

containing 0.5% DMSO only, were placed in columns 1 and 12 of each plate. Assay plates were placed into plastic boxes humidified with wet tissue and these were incubated at 37 °C in a 5% CO₂ environment.

Phenotypic changes in the schistosomula were visually recorded at 24, 48 and 72 h using a Zeiss Axiovert A1 inverted microscope (100×) as described [6, 22–24]. Briefly, simple descriptors that describe the effects of compounds on the parasites (changes in shape, motility and density) are employed. To allow for comparisons of compound activity, each descriptor is awarded a ‘severity score’ of 1 and these are added up to a maximum score of 4. Evidence of degeneracy or death is awarded the maximum score of 4 (raw data shown in Additional file 1: Table S1). Scores were averaged across the duplicate wells.

Life-cycle of *S. mansoni* at the Swiss TPH and preparation of schistosomula

The procedures to maintain the *S. mansoni* (Liberian strain) life-cycle, harvest cercariae and obtain schistosomula for *in vitro* testing are described elsewhere [8]. As detailed previously, the cercariae were mechanically transformed into schistosomula using two syringes connected by a Luer-Lok® connector (B. Braun Melsungen AG, Melsungen, Germany) [8, 18, 25]. Schistosomula were adjusted to a concentration of 50 units/100 µl and incubated for at least 12 h at 37 °C in a 5% CO₂ environment before use [14].

In vitro phenotypic assay of schistosomula at the Swiss TPH

On the day of the first drug assay, the 10 mM stock solutions of the Pathogen Box compounds were diluted (1:10) in Medium 199 (Gibco, USA) supplemented with 5% fetal calf serum (FCS; Bioconcept AG, Allschwil, Switzerland) and an antibiotic cocktail developed previously [26]. The drug plates were then stored at – 20 °C upon further use. In flat-bottom 96-well plates, each compound was tested in duplicate at a concentration of 10 µM. Every test plate included two negative controls wells containing 0.1% DMSO. Assay plates were incubated at 37 °C in a 5% CO₂ environment.

Phenotypic changes were visually recorded (10× magnification) at 24, 48 and 72 h using a previously described scoring method [8, 27]. Briefly, each well was scored using a quarter point descending scale from 3 to 0. The maximum score of 3 was assigned to wells containing schistosomula with normal movement and for which no morphological changes were apparent. A score of 2 was assigned when the overall movement in the well was reduced (or abnormally increased) and when morphological changes became apparent, i.e. increase in granularity, swelling, etc. A score of 1 was applied when almost

no movement and more severe morphological alterations were observed. Finally, a score of zero indicated worm death (no movement and a complete loss of integrity). The antischistosomal effect was expressed as a fraction of the average test scores compared to the average score of the negative control wells using Microsoft Excel as $(1 - \text{average}(\text{test})/\text{average}(\text{control}))$ [8]. For the assay to be considered valid, a minimal average score of 2 was required in the control wells.

Life-cycle of *S. mansoni* at FIOCRUZ and preparation of schistosomula

Cercariae of *S. mansoni* (LE strain) were harvested from *B. glabrata* (Barreiro strain). Schistosomula were obtained by mechanical transformation of cercariae using a protocol adapted from that previously described [19]. Briefly, cercariae were distributed into 50 ml conical tubes and allowed to settle on ice for 60 min. Cercariae were concentrated by centrifugation at 1000×g for 3 min at 4 °C, followed by resuspension in Medium 199 (without phenol red; Cat. # M3769, Sigma-Aldrich, Buchs, Switzerland) supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin (GIBCO, Thermo Fisher Scientific, Waltham, MA, USA). Cercariae were mechanically transformed by passing them four times through a 22-gauge syringe needle followed by 10 cycles of washing and sedimentation. Schistosomula were distributed in flat-bottom 96-well culture plates at 200 parasites/well in a final volume of 195 µl, and incubated at 37 °C and 5% CO₂ for 24 h in the same medium supplemented with 2% heat-inactivated FBS (GIBCO, Thermo Fisher Scientific).

In vitro phenotypic assay of schistosomula at FIOCRUZ

XTT (sodium-2,3-bis-[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide) was used as an indicator of schistosomula metabolic activity by the reduction of the yellow tetrazolium salt XTT to an orange formazan product [28, 29]. XTT was dissolved in Medium 199 without FBS to prepare a 1 mg/ml solution and the electron coupling reagent, N-methyl dibenzopyrazine methyl sulfate (PMS; Cat. # P9625, Sigma-Aldrich) was dissolved at 0.383 mg/ml in PBS. Both the XTT and PMS solutions were filtered through a 0.2 µm pore size membrane and stored at – 20 °C until use. Pathogen Box compounds were diluted to 400 µM from a 10 mM stock concentration in Medium 199 (without phenol red) in V-bottom 96-well assay plates. Afterwards, 5 µl of the diluted compounds were added to the culture plates that contained 200 parasites/well in 200 µl (10 µM final concentration of compound). Incubations were maintained for 48 h at 37 °C and 5% CO₂. The XTT labeling mixture was prepared by mixing the XTT and PMS solutions in a 50:1 ratio and 40 µl of the mixture

was added to each well of the assay plate. The incubations were continued for a further 24 h at 37 °C and 5% CO₂ and the absorbance at 450 nm (reference wavelength of 690 nm) was determined using a SpectraMax M5 microplate reader (Molecular Devices, San Jose, CA, USA). Positive and negative controls comprised heat-killed parasites and parasites incubated in the presence of 0.1% DMSO, respectively. All compounds were tested in duplicate in two independent experiments, totaling four wells for each compound. Schistosomula viability was determined using absorbance values applied to the following equation:

$$\% \text{ Viability} = \frac{(\text{Sample} - \text{Positive control})}{(\text{Negative control} - \text{Positive control})} \times 100$$

where “Sample” is the absorbance measured in each well containing parasites tested with compounds, and “Negative control” and “Positive control” represent the average absorbance measured in each of the respective controls.

Data analysis

The phenotypic scores generated by UCSD and Swiss TPH, and the percentage viability data generated by FIOCRUZ are presented in Additional file 1: Table S2. Active compounds were identified as follows: an UCSD assay score of ≥ 2 , a Swiss TPH drug effect of ≥ 0.5 and a viability of $\leq 50\%$ for the FIOCRUZ assay. The data from the three assays were also mathematically transformed (below) to obtain activity values within the same range and thus facilitate direct comparisons (Additional file 1: Table S3). Before running the transformation, the raw data were inspected. For some of the compounds tested in the Swiss TPH assay, negative viability values were obtained when the scores of the test compounds surpassed the scores in the control wells. These were converted to zero to indicate inactivity. Similarly, in the FIOCRUZ assay, compounds inducing an increase over the 100% baseline viability of the DMSO controls were not included in the data transformation process. However, some of these compounds that increased activity over baseline were also associated with antischistosomal activity in at least one of the other two assays and these are discussed below. Finally, because the scoring methods applied were opposite to one another, i.e. for the UCSD and Swiss TPH, the greater the value the more active the compound, whereas for FIOCRUZ, the reverse was the case, the raw data values were inverted to be consistent across all three groups. The data were then transformed in a span range from 0 (inactive) to 1 (most active) using the following equation:

$$\text{Transformed data} = \frac{(x - \text{median})}{(\text{max}(x) - \text{median})}$$

The median was selected as the threshold below which all the compounds were considered inactive. We employed the median instead of the minimum value of each series given that the majority of compounds were inactive. Data analysis was performed using Microsoft Office Excel and Molsoft ICM software [30]. For the transformed data, the Pearson’s correlation was calculated between pairs of data sets. The value for the F-distribution was also calculated to determine whether the correlation values occurred by chance or not. A low F-distribution value indicates that there is a low probability that the correlation between activity data occurred by chance. Finally, data for the normalized median activity score at 72 h were generated in R (version 3.6.0) using the *ggplot2* package (version 3.2.0) [31].

Results and discussion

Active and inactive Pathogen Box compounds identified among the three institutions

Schistosoma mansoni schistosomula were screened with the 400 constituent compounds of the MMV Pathogen Box by three institution-specific assays developed by UCSD, the Swiss TPH and FIOCRUZ. The data arising from each assay were then assembled for comparative analysis (Additional file 1). Our study is relevant as, to date, a plethora of schistosomula screening assays employing different methodologies (e.g. ATP and NAD(P) metabolic indicators, DNA intercalation agents such as propidium iodide, and visual- or automated image-based systems) and readouts (e.g. percentage death, EC₅₀ value or phenotypic score), have been developed such that the general interpretability of data may be constrained by the particular assay employed [9–11, 24, 28, 32–34].

The main questions to address were the extent to which the data generated are assay-specific and which compounds can be considered common actives or non-actives independent of the assay employed. Table 1 indicates the degree of concordance in the number of actives and non-actives identified across the three assays. The complete dataset is presented in Additional file 1: Table S2.

For the UCSD and Swiss TPH assays, which employ visual interpretations of anti-schistosomal activity as a function of time, there was strong concordance of 87% in identifying compounds as being either active or inactive at 24, 48 and 72 h (Table 1). When comparing the UCSD and Swiss TPH assays with the FIOCRUZ metabolic-based XTT assay at the 72 h time point, agreement remained high, i.e. 83% and 78% between FIOCRUZ and UCSD, and FIOCRUZ and SWISS TPH, respectively. When data of all three groups were compared at 72 h, the concordance was lower but still a robust 74%.

Table 1 Degree of concordance in the number of actives and non-actives identified in the Pathogen Box between the UCSD (U), Swiss TPH (S) and FIOCRUZ (F) assays

Time (h)/ Comparison	U vs S	U vs F	S vs F	U vs S vs F
24	87 (349)	na	na	na
48	87 (348)	na	na	na
72	87 (347)	83 (331)	78 (312)	74 (295)


Notes: For the times indicated, the percentage (in bold) and number of compounds (in parentheses) that were identified as active or non-active between the institutions are indicated. Comparisons between UCSD and the Swiss TPH were run on a daily basis, whereas comparisons across all three groups were possible at the 72-h time point when the XTT assay (FIOCRUZ) was completed and the data analyzed

Abbreviation: na, not applicable

This lower score might be attributable to the assay differences and parasite strains. In particular, the single metric XTT assay used by FIOCRUZ measures the oxidation of NAD(P)H as an indicator of viability [29] whereas visual interpretations of activity used by UCSD and the Swiss TPH are more holistic by identifying changes in features such as size, shape, color and motility, relative to DMSO controls.

Because both the UCSD and Swiss TPH assays employed daily observations at 24, 48 and 72 h, it was possible to note some trends for those compounds declared as active. The number of unique actives identified by UCSD decreased over time [44, 31 and 18 compounds at 24, 48 and 72 h (not counting the FIOCRUZ component at 72 h), respectively] (Fig 1; Additional file 1: Table S4). This was partly due to transiently active compounds, whereby changes noted at 24 h were no longer obvious at the later time points. Such compounds have been noted before [6, 35] and involve relatively mild changes in shape and/or motility, and with scores no greater than 2. The second trend was the increasing proportion of actives that was shared with the Swiss TPH assay as a function of time such that by 72 h, 68 active compounds were shared. These shared actives generally involved more progressive, irreversible and degenerative phenotypes (Additional file 1: Table S2). Nonetheless, at 72 h, UCSD had 18 active compounds (of which 10 registered strong scores ≥ 3), that were not identified by the Swiss TPH assay: these may be due to differences in the assay design and/or interpretation, or the parasite strain (NMRI at UCSD and Liberian at the Swiss TPH).

In contrast to the UCSD assay, the number of unique Swiss TPH actives increased as a function of time from seven at 24 h to 35 at 72 h (not counting the FIOCRUZ component at 72 h; Fig. 1; Additional file 1: Table S4). This may be due to differences in the screen assessment



methods or parasite strains. The scoring system used by UCSD is based on a range of phenotypic descriptors that encompass shape and color, in addition to motility. Although these parameters are taken into account in the Swiss TPH scoring scale, the emphasis is on motility. A closer examination of the 35 compounds identified as active by the Swiss TPH at 72 h indicates that 27 had borderline or modest scores of between 0.5 and 0.65 (Additional file 1: Table S4). In contrast, and as noted above, those actives that were shared between Swiss TPH and UCSD at 72 h and the earlier time points tended to be more potent, i.e. scores of ≥ 0.75 for Swiss TPH and ≥ 3 for UCSD.

At 72 h, the FIOCRUZ assay identified 66 actives, less than the 86 and 103 actives captured by the UCSD and Swiss TPH assays, respectively (Fig. 1; Additional file 1: Table S2). Of these FIOCRUZ actives, 35 were shared with both other assays (termed ‘core actives,’ Additional file 1: Table S5), an additional 12 actives were shared with either UCSD (six) or Swiss TPH (six), and 19 were unique. Of the 35 core actives, the majority (29) were strongly active ($\leq 30\%$ viability) in the FIOCRUZ assay and were also registered as strong actives in the other two assays (scores ≥ 3 and ≥ 0.75 for UCSD and Swiss TPH, respectively) at 72 h (Additional file 1: Table S5).

As a single-metric assay using the dye XTT, the FIOCRUZ assay is designed to specifically measure metabolic viability via NAD(P)H turnover, whereas the other two assays are based on the observational appraisals of phenotypic effects. Thus, it is anticipatable that the number of actives captured overall by the XTT assay would be less than the observation-based methods as depicted in Fig. 1. Nonetheless, the XTT assay has a robust 74% concordance with the other two assays and, in terms of automation, scalability and stringency, is particularly suitable for high-throughput formats [28]. One possibility for improving the active capture rate of the XTT assay

is to introduce a time component; however, this would require more parasites and compound, hence the current decision to use a single 72 h time point.

The finding of 19 unique XTT hits is intriguing and, apart from the possible influence of strain, the result may indicate the assay’s particular ability to identify compounds that decrease the metabolic fitness of the parasite yet are beyond visual detection in either of the other two assays. Indeed, 12 of the 19 compounds decreased viability to less than 25% of the control value (Additional file 1: Table S4). Based on a PubChem search, we note that four of the 19 XTT-active compounds inhibit *Plasmodium falciparum* L-lactate dehydrogenase, which employs NADP(H) to catalyze the interconversion of lactate and pyruvate. Interference of this metabolic pathway in the schistosome would likely be detected by the XTT assay as it could interfere with the parasite’s dehydrogenase activity.

Finally, the discussion above related to the XTT assay is based on measuring a decrease in metabolic activity from the 100% baseline. When including those compounds that increase activity above baseline, arbitrarily > 130%, an additional 34 compounds are identified, and of these, nine compounds are also active in at least one of the other assays (Additional file 1: Table S2). The association between increased metabolic rate and anti-schistosomal

activity demonstrated here has not been noted before but is worthy of consideration going forward.

To allow for direct comparisons of the data arising from the three assays, the raw activity data were transformed and ranked on a scale of 0 to 1 from least to most active (Additional file 1: Table S3). The transformed data were used to calculate the Pearson’s correlation and the respective value of the F-distribution at the different time points. Robust correlation values of 0.61, 0.63 and 0.68 were recorded at 24, 48 and 72 h, respectively, between the UCSD and Swiss TPH assay data, indicating that most of the active compounds demonstrated comparable activity. As might be anticipated with the XTT assay, the Pearson’s correlation values were more moderate when compared to either the UCSD or Swiss TPH assays at 72 h (0.46 and 0.50, respectively).

Activity of reference compounds and consistency with previous data

Included in the Pathogen Box are 26 reference compounds, i.e. compounds known to be active against and/or marketed as drugs for various microbial diseases. As shown in Fig. 2 (also Additional file 1: Table S6), eight of the 26 reference compounds were identified as active in the UCSD and Swiss TPH assays at the 72-h time point. Among these were drugs that had been previously




Fig. 2 Activity of 26 reference compounds in the Pathogen Box as measured by each assay. Data were transformed on a scale of 0 to 1 to allow for direct comparisons of the three datasets at the 72-h time point. Data for UCSD (red circles), Swiss TPH (blue squares) and FIOCRUZ (green triangles) are indicated

identified as antischistosomal, namely clofazimine [36], mefloquine [37], auranofin [38, 39] and nitazoxanide [6]. Both groups also had unique actives, namely, buparvaquone (UCSD) and nifurtimox (Swiss TPH). In the Swiss TPH assay, by contrast, PZQ generated a transformed score of 0.4 (raw score of 0.56), i.e. borderline active. The discrepancy in the activity between the two assays in detecting PZQ may be due to parasite strain or scoring methodology.

The FIOCRUZ assay returned three actives among the 26 reference compounds, namely, mefloquine, bedaquiline and clofazimine: each of these was strongly active in the other two assays. PZQ was not active in the XTT assay. In this context, it is pertinent to note that a previously employed CellTiter-Glo assay methodology which utilizes ATP as the metabolic readout did not identify PZQ or oxamniquine, an older marketed drug for treatment of schistosomiasis mansoni, as active against schistosomula [32]. This contrasts with the morphological and motility derangements induced by PZQ as detected here and previously [6, 40, 41]. We speculate that metabolic-based assays like the XTT assay which are designed to measure viability in single cells, are prone to missing important anti-schistosomal chemistries that may not affect cellular vitality/viability *per se*, but have mechanisms of action of particular consequence to complex metazoans, e.g. dysregulation of the neuromuscular system.

Interestingly, among the reference compounds that were inactive in all three assays was miltefosine, which was shown to be active against *S. mansoni* miracidia and cercariae *in vitro*, as well as against eggs, and adult worms *in vitro* and *in vivo* [42–44]. The mechanism of action

of miltefosine may depend on the interplay between parasite and host. Thus, El-Faham and colleagues [45] demonstrated that treating parasites with miltefosine enhances serological recognition of defined adult worm surface antigens. The absence of activity here may suggest a stage-specific mode of action, i.e. lacking activity against schistosomula.

Finally, of note, is the inter-assay consistency in the number of shared actives identified here and previously during the assembly of the Pathogen Box in 2015. Specifically, of 13 compounds declared by the MMV as ‘schistosomiasis active’, nine had been identified as active in the Swiss TPH assay against schistosomula after 72 h (https://www.mmv.org/sites/default/files/uploads/docs/mmv_open/Pathogen_Box_Activity_Biological_Data_Smile_s.xlsx). In the present setting and at the same time point, six of those nine actives were confirmed by the Swiss TPH assay and corroborated by the UCSD assay, with the latter identifying one additional compound (Table 2; Additional file 1: Table S7). Lastly, the FIOCRUZ assay identified five of the same six active compounds, plus three additional actives, one of which was shared with UCSD. Overall, therefore, there was solid cross-assay consistency and recall in confirming actives among those compounds previously designated by the MMV as ‘schistosomiasis active’.


Actives identified as a function of disease set

Apart from the strong representation from the MMV ‘schistosomiasis actives’ among the identified hits (Table 2), there were also representations from most of the other 11 sets designated by the MMV as being active against a particular disease (Fig. 3; Additional file 1: Table S8). As

Table 2 Actives among the three assays for 13 compounds that had been designated earlier as ‘schistosomiasis active’ by the MMV

MMV ID/Time point (h)	UCSD			Swiss TPH			FIOCRUZ (mean ± SD)
	24	48	72	24	48	72	72
MMV688761	4	4	4	1.00	1.00	1.00 ^a	− 8.0 ± 2.5
MMV688763	4	4	4	1.00	1.00	1.00 ^a	− 5.8 ± 4.9
MMV688762	4	4	4	1.00	1.00	1.00 ^a	− 3.4 ± 3.7
MMV688768	3	4	4	1.00	1.00	1.00 ^a	6.4 ± 3.3
MMV688178	0	0	2	0.60	1.00	1.00 ^a	3.1 ± 8.5
MMV676382	4	4	4	0.45	0.68	0.94 ^a	61.7 ± 11.2
MMV688270	2	4	4	0.05	0.00	0.11 ^a	39.0 ± 24.6
MMV688766	0	0	0	0.15	0.17	0.19	0.1 ± 0.4
MMV688313	0	2	0	0.10	0.17	0.28 ^a	14.7 ± 1.7
MMV688771	1	2	0	0.05	0.10	0.16	62.2 ± 7.1
MMV676536	0	0	0	0.10	0.14	0.11 ^a	75.5 ± 36.1
MMV688552	0	0	0	0.15	0.17	0.31	117.5 ± 14.6
MMV1198433	0	0	0	0.10	0.06	0.00	86.0 ± 19.9

^a Compounds that the Swiss TPH had previously determined as ‘schistosomiasis active’ vs schistosomula at 72 h during the assembly of the Pathogen Box. Active compounds are delineated in bold typeface



examples, one of four dengue compounds, MMV688543, was active, i.e. normalized median activity ≥ 0.5 , in both the UCSD and Swiss TPH assays. Among the 70 kinetoplastid compounds, eight (MMV658988, MMV676602, MMV688273, MMV688283, MMV688372, MMV689244, MMV690027 and MMV690102) were active in at least two of the assays. Similar findings were made for 11 of the 125 malaria compounds (MMV001059, MMV020391, MMV020623, MMV022029, MMV022478, MMV023233, MMV023985, MMV024114, MMV024406, MMV663250 and MMV676881), two of the 11 onchocerciasis compounds (MMV671636 and MMV676063), one of the three filariasis compounds (MMV687775) and two of 15 toxoplasmosis compounds (MMV688364 and MMV688417). Among the 116 tuberculosis compounds, 21 were active in two or more assays. Finally, among the 11 cryptosporidiosis, one hookworm, and three *Wolbachia* compound sets, actives in two or more assays were not identified (Fig. 3; Additional file 1: Table S8).

Conclusions

In this study, the Pathogen Box compound set was phenotypically screened with *S. mansoni* schistosomula using assays originating from three different institutions, namely, UCSD, the Swiss TPH and FIOCRUZ. The study's goals were to assess the degree of inter-assay variability and identify a core set of compounds that are active across the three assays performed. Among the inherent variables were parasite strain, culture medium, whether or not the parasites were pre-incubated prior to addition of compounds and the

detection system employed. In this context, field isolates of *S. mansoni* with differential susceptibilities to PZQ are known [46] and the choice of culture medium can influence the viability of schistosomula [7, 8, 17]. Evaluating the possible influences of these variables on the data, however, was not a goal of the current study. Our data show that concordance in identifying actives and non-actives was greatest between the UCSD and the Swiss TPH which employ visual assessments of phenotypic changes; however, the single-metric XTT assay employed by FIOCRUZ maintained the concordance among all groups at a robust 74%. Each assay identified unique actives, including the finding with the XTT assay that a chemically-induced increase in baseline metabolic rate is associated with antischistosomal activity. Thus, it could be argued that the best strategy to increasing the identification of active compounds is to combine an observation-based approach with the single-metric XTT assay, assuming that the resources necessary are not limiting. Overall, a common core set of 35 active compounds was identified which could be considered for further investigation. In this context, the activity of 24 out of the 35 core actives has already been tested against adult *S. mansoni* [15] with 13 compounds being active on both developmental stages (Additional file 1: Table S9). These particular hits provide starting points for further optimization.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s13071-019-3747-6>.

Additional file 1: Table S1. Descriptors and associated severity scores applied by UCSD. **Table S2.** Concordance between the 3 groups for active and inactive compounds. **Table S3.** Data transformation. **Table S4.** Unique hits per group. **Table S5.** Active compounds shared by all three groups ('core actives'). **Table S6.** Transformed activity of the reference compounds. **Table S7.** Comparisons with data previously generated for the same compounds. **Table S8.** Transformed activity by disease set. **Table S9.** Core active compounds compared to activity measured previously by the Swiss TPH against adult *S. mansoni*.

Abbreviations

ATP: adenosine triphosphate; DMSO: dimethyl sulfoxide; DNA: deoxyribonucleic acid; EC50: half maximal effective concentration; FBS: fetal bovine serum; FCS: fetal calf serum; FIOCRUZ: Fundação Oswaldo Cruz; MMV: Medicines for Malaria Venture; NAD(P): nicotinamide adenine dinucleotide (phosphate); NMRI: Naval Medical Research Institute; PBS: phosphate-buffered saline; PMS: N-methyl dibenzopyrazine methyl sulfate; PZQ: praziquantel; Swiss TPH: Swiss Tropical and Public Health Institute; UCSD: University of California San Diego; XTT: sodium-2,3-bis-[2-methoxy-4-nitro-5-sulphophenyl]-2H-tetrazolium-5-carboxanilide.

Acknowledgements

ChemAxon's JChem for Office (Excel; Version 15.1.1900.1773) was used to display the structures shown in Additional file 1: Table S1 (<http://www.chemaxon.com>).

Authors' contributions

All authors designed the studies and analyzed the data. PHNA, VP, MP, BMS, SM, MP and CRC performed the screening experiments. MM, PHNA, VP, MMM, JK and CRC drafted the first version of the manuscript. All authors read and approved the final manuscript.

Funding

Screens at UCSD were made possible in part by NIH-NIAID R21AI126296 and OPP1171488 from the Bill and Melinda Gates Foundation to CRC. The research at FIOCRUZ was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brasil (CAPES), Finance Code 001, 003/2014 and CNPq Research Productivity Fellowship 302518/2018-5 to MMM. JK is grateful to the European Research Council (ERC-2013-CoG 614739-A_HERO).

Availability of data and materials

The data supporting the conclusions of this article are included within the article.

Ethics approval and consent to participate

We acknowledge the MMV for designing and supplying the Pathogen Box. Vertebrate maintenance and handling at the UCSD Animal Care Facility were in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) at UCSD. The procedures involving laboratory animals at the Swiss TPH were approved by the Canton of Basel-Stadt and met the ethical standards set both by the cantonal and Swiss veterinary authorities (license no. 2070). They were also performed according to the 3Rs principles (<http://www.nc3rs.org.uk>). At FIOCRUZ, the experiments involving laboratory animals were carried out according to Brazilian national guidelines for the use of animals in scientific research. Animal experiments carried out for this report were approved by the Ethics Commission for Animal Use (CEUA) under the license number LW-32/17.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA. ² Laboratório de Helmintologia e Malacologia Médica, René Rachou Institute, FIOCRUZ, Belo Horizonte, Minas Gerais, Brazil. ³ Department

of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, P.O. Box, 4002 Basel, Switzerland. ⁴ University of Basel, P.O. Box, 4003 Basel, Switzerland. ⁵ Present Address: Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, NA, Italy.

Received: 12 August 2019 Accepted: 11 October 2019

Published online: 22 October 2019

References

- WHO. Crossing the Billion. Preventive chemotherapy for neglected tropical diseases. Geneva: World Health Organization; 2017. http://www.who.int/neglected_diseases/resources/9789240696471/en/. Accessed 5 Sept 2017.
- Caffrey CR. Chemotherapy of schistosomiasis: present and future. *Curr Opin Chem Biol.* 2007;11:433–9.
- McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou X-N. Schistosomiasis. *Nat Rev Dis Primer.* 2018;4:13.
- Caffrey CR. Schistosomiasis and its treatment. *Future Med Chem.* 2015;7:675–6.
- Wolfe AR, Neitz RJ, Burlingame M, Suzuki BM, Lim KC, Scheideler M, et al. TPT sulfonate, a single, oral dose schistosomicidal prodrug: in vivo efficacy, disposition and metabolic profiling. *Int J Parasitol Drugs Drug Resist.* 2018;8:571–86.
- Abdulla M-H, Ruelas DS, Wolff B, Snedecor J, Lim K-C, Xu F, et al. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. *PLoS Negl Trop Dis.* 2009;3:e478.
- Tekwu EM, Anyan WK, Boamah D, Baffour-Awuah KO, Keyetat Tekwu S, Penlap Beng V, et al. Mechanically produced schistosomula as a higher-throughput tools for phenotypic pre-screening in drug sensitivity assays: current research and future trends. *Biomark Res.* 2016;4:21.
- Lombardo FC, Pasche V, Panic G, Endriss Y, Keiser J. Life cycle maintenance and drug-sensitivity assays for early drug discovery in *Schistosoma mansoni*. *Nat Protoc.* 2019;14:461–81.
- Asarnow D, Rojo-Arreola L, Suzuki BM, Caffrey CR, Singh R. The QDREC web server: determining dose-response characteristics of complex macroparasites in phenotypic drug screens. *Bioinformatics.* 2015;31:1515–8.
- Panic G, Flores D, Ingram-Sieber K, Keiser J. Fluorescence/luminescence-based markers for the assessment of *Schistosoma mansoni* schistosomula drug assays. *Parasites Vectors.* 2015;8:624.
- Paveley RA, Mansour NR, Hallyburton I, Bleicher LS, Benn AE, Mikic I, et al. Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. *PLoS Negl Trop Dis.* 2012;6:e1762.
- Voorhis WCV, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, et al. Open source drug discovery with the Malaria Box compound collection for neglected diseases and beyond. *PLOS Pathog.* 2016;12:e1005763.
- Duffy S, Sykes ML, Jones AJ, Shelper TB, Simpson M, Lang R, et al. Screening the Medicines for Malaria Venture Pathogen Box across multiple pathogens reclassifies starting points for open-source drug discovery. *Antimicrob Agents Chemother.* 2017;61:e00379-17.
- Ingram-Sieber K, Cowan N, Panic G, Vargas M, Mansour NR, Bickle QD, et al. Orally active antischistosomal early leads identified from the open access Malaria Box. *PLoS Negl Trop Dis.* 2014;8:e2610.
- Pasche V, Laleu B, Keiser J. Early antischistosomal leads identified from in vitro and in vivo screening of the medicines for Malaria Venture Pathogen Box. *ACS Infect Dis.* 2019;5:102–10.
- Pasche V, Laleu B, Keiser J. Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against *Schistosoma mansoni*. *Parasites Vectors.* 2018;11:298.
- Štefanić S, Dvořák J, Horn M, Braschi S, Sojka D, Ruelas DS, et al. RNA interference in *Schistosoma mansoni* schistosomula: selectivity, sensitivity and operation for larger-scale screening. *PLoS Negl Trop Dis.* 2010;4:e850.
- Colley DG, Wikel SK. *Schistosoma mansoni*: simplified method for the production of schistosomules. *Exp Parasitol.* 1974;35:44–51.
- Basch P. Cultivation of *Schistosoma mansoni* in vitro. 1. Establishment of cultures from cercariae and development until pairing. *J Parasitol.* 1981;67:179–85.

20. Long T, Neitz RJ, Beasley R, Kalyanaraman C, Suzuki BM, Jacobson MP, et al. Structure-bioactivity relationship for benzimidazole thiophene inhibitors of Polo-like kinase 1 (PLK1), a potential drug target in *Schistosoma mansoni*. *PLoS Negl Trop Dis*. 2016;10:e0004356.
21. Long T, Rojo-Arreola L, Shi D, El-Sakkary N, Jarnagin K, Rock F, et al. Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target. *PLoS Negl Trop Dis*. 2017;11:e0005680.
22. Rojo-Arreola L, Long T, Asarnow D, Suzuki BM, Singh R, Caffrey CR. Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. *PLoS ONE*. 2014;9:e87594.
23. Glaser J, Schurigt U, Suzuki BM, Caffrey CR, Holzgrabe U. Anti-schistosomal activity of cinnamic acid esters: eugenyl and thymyl cinnamate induce cytoplasmic vacuoles and death in schistosomula of *Schistosoma mansoni*. *Molecules*. 2015;20:10873–83.
24. Weeks JC, Roberts WM, Leasure C, Suzuki BM, Robinson KJ, Currey H, et al. Sertraline, paroxetine, and chlorpromazine are rapidly acting anthelmintic drugs capable of clinical repurposing. *Sci Rep*. 2018;8:975.
25. Milligan JN, Jolly ER. Cercarial transformation and in vitro cultivation of *Schistosoma mansoni* schistosomules. *J Vis Exp*. 2011;54:3191.
26. Mäser P, Grether-Bühler Y, Kaminsky R, Brun R. An anti-contamination cocktail for the in vitro isolation and cultivation of parasitic protozoa. *Parasitol Res*. 2002;88:172–4.
27. Ramirez B, Bickle Q, Yousif F, Fakorede F, Mouries M-A, Nwaka S. Schistosomes: challenges in compound screening. *Expert Opin Drug Discov*. 2007;2:553–61.
28. Aguiar PHN, Fernandes NMGS, Zani CL, Mourão MM. A high-throughput colorimetric assay for detection of *Schistosoma mansoni* viability based on the tetrazolium salt XTT. *Parasites Vectors*. 2017;10:300.
29. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. *Cancer Res*. 1988;48:4827–33.
30. Abagyan R, Totrov M, Kuznetsov D. ICM - a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. *J Comput Chem*. 1994;15:488–506.
31. Wickham H. *ggplot2: elegant graphics for data analysis*. New York: Springer; 2016. <https://ggplot2.tidyverse.org>. Accessed 2 Aug 2019.
32. Lalli C, Guidi A, Gennari N, Altamura S, Bresciani A, Ruberti G. Development and validation of a luminescence-based, medium-throughput assay for drug screening in *Schistosoma mansoni*. *PLoS Negl Trop Dis*. 2015;9:e0003484.
33. Peak E, Chalmers IW, Hoffmann KF. Development and validation of a quantitative, high-throughput, fluorescent-based bioassay to detect *Schistosoma* viability. *PLoS Negl Trop Dis*. 2010;4:e759.
34. Rinaldi G, Loukas A, Brindley PJ, Irelan JT, Smout MJ. Viability of developmental stages of *Schistosoma mansoni* quantified with xCELLigence worm real-time motility assay (xWORM). *Int J Parasitol Drugs Drug Resist*. 2015;5:141–8.
35. Fonseca NC, da Cruz LF, da Silva Villela F, do Nascimento Pereira GA, de Siqueira-Neto JL, Kellar D, et al. Synthesis of a sugar-based thiosemicarbazone series and structure–activity relationship versus the parasite cysteine proteases Rhodesain, Cruzain, and *Schistosoma mansoni* Cathepsin B1. *Antimicrob Agents Chemother*. 2015;59:2666–77.
36. Panic G, Vargas M, Scandale I, Keiser J. Activity profile of an FDA-approved compound library against *Schistosoma mansoni*. *PLoS Negl Trop Dis*. 2015;9:e0003962.
37. Keiser J, Chollet J, Xiao S-H, Mei J-Y, Jiao P-Y, Utzinger J, et al. Mefloquine—an aminoalcohol with promising antischistosomal properties in mice. *PLoS Negl Trop Dis*. 2009;3:e350.
38. Alger HM, Williams DL. The disulfide redox system of *Schistosoma mansoni* and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. *Mol Biochem Parasitol*. 2002;121:129–39.
39. Angelucci F, Sayed AA, Williams DL, Boumis G, Brunori M, Dimastrogiovanni D, et al. Inhibition of *Schistosoma mansoni* thioredoxin-glutathione reductase by auranofin structural and kinetic aspects. *J Biol Chem*. 2009;284:28977–85.
40. Lee H, Moody-Davis A, Saha U, Suzuki BM, Asarnow D, Chen S, et al. Quantification and clustering of phenotypic screening data using time-series analysis for chemotherapy of schistosomiasis. *BMC Genomics*. 2012;13(Suppl. 1):S4.
41. Singh R, Pittas M, Heskia I, Xu F, McKerrow J, Caffrey CR. Automated image-based phenotypic screening for high-throughput drug discovery. In: 2009 22nd IEEE international symposium on computer-based medical systems; 2009. p. 1–8.
42. Bertão HG, da Silva RAR, Padilha RJR, de Azevedo Albuquerque MCP, Rádis-Baptista G. Ultrastructural analysis of miltefosine-induced surface membrane damage in adult *Schistosoma mansoni* BH strain worms. *Parasitol Res*. 2012;110:2465–73.
43. Eissa MM, El-Moslemany RM, Ramadan AA, Amer EI, El-Azzouni MZ, El-Khordagui LK. Miltefosine lipid nanocapsules for single dose oral treatment of schistosomiasis mansoni: a preclinical study. *PLoS ONE*. 2015;10:e0141788.
44. Eissa MM, El-Azzouni MZ, Amer EI, Baddour NM. Miltefosine, a promising novel agent for schistosomiasis mansoni. *Int J Parasitol*. 2011;41:235–42.
45. El-Faham MH, Eissa MM, Igetei JE, Amer EI, Liddell S, El-Azzouni MZ, et al. Treatment of *Schistosoma mansoni* with miltefosine in vitro enhances serological recognition of defined worm surface antigens. *PLoS Negl Trop Dis*. 2017;11:e0005853.
46. Couto FFB, Coelho PMZ, Araujo N, Kusel JR, Katz N, Mattos ACA. Use of fluorescent probes as a useful tool to identify resistant *Schistosoma mansoni* isolates to praziquantel. *Parasitology*. 2010;137:1791–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

